AKT1 and ovarian carcinoma: The PI3K/AKT/mTOR pathway is a well-known pathway involved in ovarian cancer carcinogenesis and mTOR as a drug target (e.g.: Rapamycin, Everolimus, and Temsirolimus) is being investigated in clinical trials [44,45].